Psychobiotics: do probiotics actually help depression and anxiety?

The term “psychobiotic” was coined in 2013 by Dinan, Stanton and Cryan, in a Biological Psychiatry paper, for a tightly drawn idea: a live organism that, taken in adequate amounts, produces a mental-health benefit in people with psychiatric illness. The concept rode the rise of the gut–brain axis, and the marketing has since stretched it to cover almost any supplement promising calm or focus. So it’s worth asking the plain question the trials are designed to answer: can a probiotic actually move depression or anxiety — and if so, for whom?

The mechanism is not the problem

The plumbing is real. As Sarkar et al. (2016) and the comprehensive Cryan et al. (2019) review lay out, gut microbes can signal to the brain through the vagus nerve, immune messengers, and the metabolism of neurotransmitter precursors such as tryptophan, the raw material for serotonin. There are believable routes by which a microbe could influence mood. The question is never whether a path exists — it’s whether a given pill, in a real person, travels it to a measurable end.

What the meta-analyses actually find

Pool the controlled trials and a consistent, modest picture emerges. Liu, Walsh & Sheehan (2019) found probiotics produced a small but statistically significant reduction in depression (effect size around −0.24) and a smaller one in anxiety — while prebiotics, on their own, were no better than placebo. The crucial detail is in the subgroups: the benefit was far larger in clinically diagnosed or psychiatric populations than in general-community samples.

Two more meta-analyses sharpen that point. Goh et al. (2019), pooling 19 double-blind trials, found probiotics improved depressive symptoms — but the effect was significant only in patients with major depressive disorder, not in other conditions or in healthy people. And Ng et al. (2018) found no significant overall mood effect, with a benefit appearing only on closer look in mild-to-moderate depression and none at all in healthy individuals. Across all three, the same line keeps surfacing.

The signal is real but small, and it concentrates where there is something to fix. Probiotics nudge mood in people who are clinically depressed — and do close to nothing for the already-well. “Psychobiotics for everyday mood” is the part the data do not support.

The flagship trials, in proportion

The often-cited early human trials are smaller and softer than the headlines suggest. Steenbergen et al. (2015) gave a multispecies probiotic to 40 healthy adults and saw reduced “cognitive reactivity to sad mood” — a surrogate measure of rumination, not clinical depression. Allen et al. (2016) reported that Bifidobacterium longum 1714 blunted the cortisol and anxiety response to an acute stressor — in 22 healthy men, a crossover design measuring acute stress, not a disorder. These are interesting proofs of concept. They are not evidence that a supplement treats a diagnosis.

The newest, most honest data point

The most recent reputable trial is candid about its own limits. Nikolova et al. (2023), in JAMA Psychiatry, added a 14-strain probiotic to standard antidepressants in 49 adults with major depression who hadn’t fully responded. It was well tolerated, and the mood scores moved in the probiotic’s favour — but the authors are explicit that this was a pilot designed to estimate effect sizes, not to prove efficacy. Promising, hedged, and waiting on a larger trial. That is the honest state of the art.

Three things to hold onto

Strain-specificity is not a detail. Results from one strain, dose and formulation do not transfer to another — “probiotics help depression” is far too coarse a claim to act on, and multi-strain products sometimes outperform single strains in these analyses. It is exactly this problem that is pushing the industry toward strain-level precision. Most of the strong-looking trials are small, short and run in healthy volunteers using surrogate endpoints, with the usual heterogeneity and publication-bias concerns. And the regulation is unforgiving for a reason: in the U.S. these are dietary supplements, which by law may not claim to treat a disease. No probiotic is FDA-approved as a drug for depression or anxiety; “psychobiotic” is a research term, not an approved therapeutic category.

The honest bottom line

The most defensible reading: in people who are clinically depressed, a probiotic may offer a small, real, adjunctive benefit — alongside, never instead of, evidence-based care. For everyone else, the case that a “mood probiotic” will lift an ordinary bad week is mechanistically plausible and empirically thin. The gut–brain axis is genuine; the pill that reliably exploits it for mental health is still, mostly, ahead of the data. For how the underlying terms are used precisely, see our prebiotic / probiotic / postbiotic guide.